173 related articles for article (PubMed ID: 10589274)
21. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
[TBL] [Abstract][Full Text] [Related]
22. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of spironolactone in a specialized heart failure clinic.
Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
[TBL] [Abstract][Full Text] [Related]
25. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
Vizzardi E; Nodari S; Caretta G; D'Aloia A; Pezzali N; Faden G; Lombardi C; Raddino R; Metra M; Dei Cas L
Am J Med Sci; 2014 Apr; 347(4):271-6. PubMed ID: 24196866
[TBL] [Abstract][Full Text] [Related]
26. Eplerenone in patients with systolic heart failure and mild symptoms.
Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
[TBL] [Abstract][Full Text] [Related]
27. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Talatinian A; Chow SL; Heywood JT
Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
[TBL] [Abstract][Full Text] [Related]
28. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
Macdonald JE; Kennedy N; Struthers AD
Heart; 2004 Jul; 90(7):765-70. PubMed ID: 15201246
[TBL] [Abstract][Full Text] [Related]
29. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis.
Baliga RR; Ranganna P; Pitt B; Koelling TM
J Card Fail; 2006 May; 12(4):250-6. PubMed ID: 16679256
[TBL] [Abstract][Full Text] [Related]
30. Spironolactone in congestive heart failure.
Soberman JE; Weber KT
Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
[TBL] [Abstract][Full Text] [Related]
31. The effect of digoxin on mortality and morbidity in patients with heart failure.
Digitalis Investigation Group
N Engl J Med; 1997 Feb; 336(8):525-33. PubMed ID: 9036306
[TBL] [Abstract][Full Text] [Related]
32. [Aldosterone antagonists for all patients with heart failure?].
Bauersachs J
MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
[No Abstract] [Full Text] [Related]
33. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Ramires FJ; Mansur A; Coelho O; Maranhão M; Gruppi CJ; Mady C; Ramires JA
Am J Cardiol; 2000 May; 85(10):1207-11. PubMed ID: 10802002
[TBL] [Abstract][Full Text] [Related]
34. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
[TBL] [Abstract][Full Text] [Related]
35. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
[TBL] [Abstract][Full Text] [Related]
36. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Zannad F; Dousset B; Alla F
Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
[TBL] [Abstract][Full Text] [Related]
37. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
Haller C
Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
[TBL] [Abstract][Full Text] [Related]
38. The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
James R; Guillot E; Garelli-Paar C; Huxley J; Grassi V; Cobb M
J Vet Cardiol; 2018 Feb; 20(1):1-12. PubMed ID: 29277469
[TBL] [Abstract][Full Text] [Related]
39. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
[TBL] [Abstract][Full Text] [Related]
40. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
